Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MHLW Lifts All-Case Surveillance for Novartis' Lucentis
March 18, 2013
- Nihon Pharmaceutical Industry Voluntarily Recalls Revinbace Tablets 10 mg, Temporarily Suspends Sales
March 18, 2013
- Eisai Eyes Sales of 50 Billion Yen in Asian Generic Biz within 5 Years
March 15, 2013
- Shionogi, Kyoto University to Collaborate on Research for AD Treatment
March 15, 2013
- Eli Lilly Japan Files Tadalafil for BPH, 3rd NDA for Same API
March 15, 2013
- Astellas Files NDA in Japan for SGLT-2 Inhibitor Ipragliflozin
March 15, 2013
- API Corporation to Establish Production Base for Drug Substances, Intermediates in India
March 15, 2013
- Astellas Grants US Firm Global Rights to Ceftolozane
March 14, 2013
- Eli Lilly Japan’s 2012 Sales Surge 10% on Brisk Zyprexa; NHI Price Cut Countered
March 14, 2013
- Sanofi Japan Aims to Enhance Leadership Status in Diabetes Sector with GLP-1, President Says
March 14, 2013
- A Number of Blockbuster Candidates Emerging from Japanese Pharmas’ In-house R&D: Dr Nakamura of Pharma Forum Institute
March 14, 2013
- Astellas, Ambit to Terminate Development Collaboration for FLT3 Kinase Inhibitors
March 14, 2013
- Biosimilar Makers Getting Premium-Linked Inquiries from Medical Institutions
March 13, 2013
- Overseas Business Making Up for Sluggish Domestic Market; Weaker Yen Could Add Further Boost in 4th Quarter
March 13, 2013
- CSOs Diversifying Services in Japan amid Increasing Use of CMRs
March 12, 2013
- Wholesalers’ Price Negotiations Likely to Be Carried Over to New Fiscal Year; Unsettlement Rates Could Hit Double-Digit Figures
March 12, 2013
- Kyowa Kirin to Start Constructing Manufacturing Plant in Gunma in May
March 12, 2013
- Hisamitsu to File for Chronic Pain for Fentos Tape in 2013
March 12, 2013
- Nihon Chouzai Obtains Loan from Development Bank of Japan to Strengthen Production Base for Generic Drugs
March 12, 2013
- Dolutegravir Shows Significant Superior Efficacy Compared to Raltegravir in PIII Study: Shionogi
March 12, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…